Paul Perreault, CSL Behring CEO

CSL CEO Paul Per­reault de­ter­mined to grow plas­ma col­lec­tion af­ter full-year sales dip

As the ink dries on CSL’s $11.7 bil­lion Vi­for buy­out, the com­pa­ny post­ed a dip in prof­its, due in part to a drop in plas­ma do­na­tions amid the pan­dem­ic.

How­ev­er, CEO Paul Per­reault as­sured in­vestors and an­a­lysts on the full-year call that the team has left “no stone un­turned” when as­sess­ing op­tions to grow plas­ma vol­umes. The chief ex­ec­u­tive al­so spelled out pos­i­tive re­sults for the com­pa­ny’s mon­o­clon­al an­ti­body garadacimab in hered­i­tary an­gioede­ma (HAE), though he isn’t re­veal­ing the ex­act num­bers just yet.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.